消息面上，基石药业-B发布公告，于2025年4月25日至30日，美国癌症研究协会 (AACR)年会在美国芝加哥举行。基石药业携五款自主研发的管线2.0创新产品亮相本次大会，并通过壁报展示其最新临床前研究成果，包括三抗CS2009 (PD-1/VEGF/CTLA-4三特异性抗体)、双抗CS2011 (EGFR/HER3双特异性抗体)及出自公司自有抗体偶联药物 ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

在肿瘤免疫治疗领域，PD-1、VEGFA和CTLA-4是经临床验证的有效靶点，三者间的协同机制可实现多维度的抗肿瘤效应。抗PD-1与CTLA-4双重阻断已在包括非小 ...

智通财经APP获悉，5月6日，基石药业(02616)，一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，宣布公司在2025年美国癌症 ...

PD-1, VEGFA, and CTLA-4 are clinically validated targets for immunotherapies, which can exert complementary, multi-dimensional anti-tumor effects through synergistic mechanisms. Blockade of PD-1 ...

Article continues below The team found that these senescent cells accumulate because the immune system struggles to remove them effectively, a problem linked to a protein known as CTLA4 ...

The reason for this is said to be down to a protein called CTLA4, which works like an emergency brake, slowing down the immune system. The researchers used a cancer drug called ipilimumab to block ...

这里说的免疫治疗指的是PD-1，CAR-T...这类免疫疗法。 自从抗CTLA4单抗免疫检查点抑制剂上市用于恶性黑色素瘤治疗以来，抗CTLA4和抗PD-1免疫疗法一路 ...

WBG选用：Breathe塞恩；Tian潘森；Xiaohu岩雀；Light韦鲁斯；Erha烈娜塔 23分钟，TheShy再次开出完美大招，IG上中野冲溃阵型打出2换4 ...